covid 19 antibody testing

Displaying 8 studies

  • Antibodies against COVID (enrolling by invitation) Rochester, MN

    The study is being done to identify how many Healthcare workers develop antibodies against the SARS-CoV 2 virus over a 6 month period

  • Development of Potential COVID-19 Vaccine and Serological Assay Rochester, MN

    Our group has explored the use of genomic RNA/phage display libraries derived from primary human malignant melanoma cells as a means of identifying antibody detectable targets on cancer cells (cancer vaccines or antibody guided therapeutics).  In this approach, we isolate and affinity-column immobilize the IgG fraction from patient serum before and after immune therapy for melanoma, and expose the immobilized antibodies to bacteriophage expressing approximately 2x109 overlapping cDNA sequences of paired (same patient derived plasma and cancer cells) melanoma genomic RNA.  Phage, expressing melanoma cDNA express the proteins/peptides on their capsid are “recognized” by the immobilized antibodies are retained in ...

  • COVID-19 Serological Assay Validation Rochester, MN

    The purpose of this research is to evaluate multiple new tests for detection of antibodies to SARS-CoV-2, the cause of COVID19, in blood samples.

  • A COVID Study to Compare Impact of Zinc Supplementation versus Multivitamin to Support Immune Health Rochester, MN

    The purpose of this study is compare high dose (69.6 mg/day) Zinc to multivitamin supplementation on immune health as used by primary health care staff and individuals over 50 years old identified, by hypothesis generated from observations among the pandemic to date, as being at risk populations to COVID-19. In order to ensure consistent nutritional supplementation, the PreserVision AREDS formulation gel tabs will be recommended for those randomized to Zinc and the Adult (under 50) Centrum formulation recommended for those randomized to multivitamin.

  • A Study to Analyze Algorithms for Evaluating Early Detection of SARS-CoV/COVID-19 Infection in Critical Service Employees Rochester, MN

    The purpose of this study is to develop algorithms that will enable earlier identification and testing triggers for COVID-19 in otherwise asymptomatic patients, and to identify baseline characteristics from patients that ultimately test positive for COVID-19 that may predict clinical trajectory during the evolution of disease.

     

  • COVID-19 Residual Biobank Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL

    This Research Repository will prospectively collect residual (waste) blood, urine, and stool specimens remaining from clinician order testing and corresponding clinical and patient provided data from COVID-19 patients with confirmed or suspected infection with the novel SARS-CoV-2 virus to enable high quality research.  Participants will be approached for consent by the study team after the samples are identified. Samples and data from this repository will be made available to researchers with IRB-approved research projects after review and approval by the COVID-19 Access Committee.  We believe this biobank will enable high quality research to improve clinical practice and patient outcomes.

  • A Study to Assess the Culture, PCR, Serology and Symptoms of COVID-19 Scottsdale/Phoenix, AZ

    The purpose of this study is to understand when patients are shedding active COVID virus RNA as detectable by viral culture, and if there are any correlates of the cessation of active viral shedding, such as presence of certain immunoglobulins.

    Additionally, this study will take a discovery approach to the immune response to better understand how the body recovers or worsens during disease, and if there are opportunities to use that knowledge to develop treatments.

     

  • A Study to Evaluate Early Detection of SARS-CoV-2/COVID-19 in High Risk Radiation Oncology Patients Rochester, MN

    The purpose of this study is to develop algorithms that will enable earlier identification and testing triggers for COVID-19 in otherwise asymptomatic patients, and to identify baseline characteristics from patients who ultimately test positive for COVID-19 that may predict clinical trajectory during the evolution of disease.

     

.

Mayo Clinic Footer